Full-Time

Clinical Development Medical Director

Posted on 3/16/2025

Exelixis

Exelixis

1,001-5,000 employees

Develops cancer therapies and treatments

Compensation Overview

$221k - $313k/yr

+ Bonus + Sales-based Incentive Plan

Senior

King of Prussia, PA, USA + 1 more

More locations: Alameda, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MD (board certification or eligibility in Oncology or Hematology/Oncology desirable but not essential) required with a minimum of 5 years of post-residency experience.
  • Equivalent combination of education and experience
  • Drug development experience in biotechnology or pharmaceutical industry, or a combination of academia and industry.
  • Hands-on experience in the design, execution, and reporting of controlled clinical trials in oncology.
  • Participated in clinical oncology studies with molecular targeted or immunological therapies.
  • Understanding of basic science relevant to clinical oncology (biochemistry, immunology, molecular biology and/or genetics).
Responsibilities
  • Design, prepare and initiate study protocols and other required documentation in compliance with project plans, federal regulations, GCP and good medical practice.
  • Act as medical monitor for company sponsored trials.
  • Support project teams with therapeutic area specific information.
  • Collaborate with internal safety group in analyzing and reporting of safety data from clinical trials.
  • Analyze and interpret other clinical trial data and prepare reports for regulatory agencies and publication.
  • Interact with key opinion leaders and investigators in relevant disease specific area.
  • Ensure consistency of scientific and development strategies for oncology products in development.
  • Maintain the highest level of scientific and clinical knowledge in relevant disease specific area.
Desired Qualifications
  • Board certification or eligibility in Oncology or Hematology/Oncology desirable but not essential.

Exelixis develops and commercializes medicines specifically for cancer treatment. The company creates therapies that target various biological pathways and can be used in combination with other treatments, focusing on providing effective and tolerable options for patients with advanced cancers, such as renal cell carcinoma. Exelixis conducts extensive research, clinical trials, and seeks regulatory approvals to introduce new drugs to the market. Unlike many competitors, Exelixis emphasizes combination regimens in its treatment approach. The goal of Exelixis is to enhance patient outcomes and offer hope for remission through its drug development efforts.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine aligns with Exelixis' innovative strategy.
  • AI-driven drug discovery accelerates Exelixis' R&D efforts.
  • FDA's expedited approval pathways benefit Exelixis' drug pipeline.

What critics are saying

  • Emerging competitors may impact Exelixis' market share and revenue.
  • Potential clinical trial delays could affect Exelixis' timelines and projections.
  • Patent expirations may lead to generic competition, reducing revenue.

What makes Exelixis unique

  • Exelixis focuses on innovative cancer treatments targeting multiple pathways.
  • The company emphasizes combination regimens for more effective cancer therapies.
  • Exelixis has a strong pipeline in renal cell carcinoma treatments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Company News

Defense World
Mar 9th, 2025
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC makes new investment in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Feb 13th, 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Exelixis to participate in the Citi 2025 Virtual Oncology Leadership Summit.

MarketBeat
Jan 7th, 2025
Range Financial Group LLC Invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Jan 6th, 2025
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

MarketBeat
Dec 5th, 2024
NFJ Investment Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

NFJ Investment Group LLC makes new Investment in Exelixis, Inc. (NASDAQ:EXEL).

INACTIVE